Sahil Munjal,Stephen Ferrando
Sahil Munjal
We are presenting a case of 37-year-old male with schizoaffective disorder who developed myocarditis within 3 weeks of starting on clozapine for his treatment resistant psychosis. The patient also had a positive titer for Influenza A which ...
A Guide to the Management of Clozapine-Related Tolerability and Safety Concerns [0.03%]
氯氮平耐受性和安全问题处理指南
Leslie Citrome,Joseph P McEvoy,Stephen R Saklad
Leslie Citrome
Clozapine is a highly effective antipsychotic medication, which provides a range of significant benefits for patients with schizophrenia, and is the standard of care for treatment-resistant schizophrenia as well as for reducing the risk of ...
Nigel Bark,Nicholas Lawson,Eileen Trigoboff et al.
Nigel Bark et al.
So far, demographic variables have not consistently been found to predict clinical response to antipsychotics. This study examines some differences in response to ziprasidone, which has been shown to be effective, with a better metabolic si...
Highlights from the Biennial International Congress on Schizophrenia Research (ICOSR), March 28-April 1, 2015 [0.03%]
2015年国际精神分裂症研究大会亮点摘要
Matej Markota,Urvakhsh Mehta,Michele Solis
Matej Markota
The 2015 International Congress on Schizophrenia Research, held in Colorado Springs, Colorado, attracted over 1,000 attendees from March 28-April 1, 2015. With the gracious assistance of Congress directors Carol Tamminga and Chuck Schulz, a...
Clinical news [0.03%]
临床快讯
Peter F Buckley
Peter F Buckley
Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies [0.03%]
长期注射阿立哌唑维持治疗精神分裂症患者的效果：两项多中心、随机和双盲研究结果
John M Kane,Raymond Sanchez,Ross A Baker et al.
John M Kane et al.
Objectives: To further characterize the clinical profile of long-term treatment with aripiprazole once-monthly 400 mg (AOM 400) by examining patient-centered outcomes in adults with schizophrenia. ...
Randomized Controlled Trial
Clinical schizophrenia & related psychoses. 2015 Summer;9(2):79-87. DOI:10.3371/CSRP.KASA.022015 2015
Drug development update [0.03%]
药物研发进展更新
Peter F Buckley
Peter F Buckley
Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia [0.03%]
switching to iloperidone：一项针对500例精神分裂症患者的开放标签随机临床试验的综合临床观察结果（为期12周）
Leslie Citrome,Peter J Weiden,Gus Alva et al.
Leslie Citrome et al.
Objective: To describe secondary analyses from a 12-week, randomized, open-label trial where adult schizophrenia outpatients receiving risperidone, olanzapine, or aripiprazole were switched to iloperidone. ...
Randomized Controlled Trial
Clinical schizophrenia & related psychoses. 2015 Jan;8(4):183-95. DOI:10.3371/CSRP.CIWE.103114 2015
David J Castle,Jens-Kristian Slott Jensen
David J Castle
Background: Although depressive symptoms are a frequently occurring phenomenon in schizophrenia, effective treatments remain an area of clinical need. Obj...
Randomized Controlled Trial
Clinical schizophrenia & related psychoses. 2015 Apr;9(1):13-20. DOI:10.3371/CSRP.CAJE.103114 2015
Imon Paul,Vinay Basavaraju,Janardhanan C Narayanaswamy et al.
Imon Paul et al.